Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the anticipated market size of the hematologic malignancies testing industry over the next few years?
The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.16 billion in 2024 to $3.59 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to rising incidence of blood cancers, increasing awareness of early cancer detection, growing use of flow cytometry and molecular diagnostics, expansion of hematology testing in hospitals and laboratories, and growing availability of reimbursement for cancer diagnostics.
The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to growing demand for personalized cancer treatment, increasing adoption of next-generation sequencing, rising healthcare spending in emerging markets, expansion of precision oncology programs, and increasing number of clinical trials for blood cancer therapies. Major trends in the forecast period include advancements in molecular testing technologies, development of automated and high-throughput diagnostic platforms, research and development in hematologic malignancies, integration of artificial intelligence in test analysis, and innovations in liquid biopsy techniques for blood cancers.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24234&type=smp
What emerging drivers are expected to shape the future of the hematologic malignancies testing market?
The rising number of cancer diagnoses is expected to propel the growth of the hematologic malignancies testing market going forward. Cancer diagnoses refer to the process of identifying the presence, type, and stage of cancer in a patient using various medical tests and evaluations such as imaging, laboratory tests, and biopsies. The rising number of cancer diagnoses is due to improved access to screening programs and heightened public awareness, resulting in earlier detection. Hematologic malignancies testing is helpful in cancer diagnoses by enabling early detection, accurate classification, and monitoring of blood-related cancers, ultimately guiding targeted treatment decisions and improving patient outcomes. For instance, according to American Cancer Society, an US-based a nonprofit organization, in 2024, over 2 million new cancer cases are diagnosed in the US, a 4% increase from previous years. Therefore, the rising number of cancer diagnoses drives growth in the hematologic malignancies testing market.
What emerging segments are shaping the future landscape of the hematologic malignancies testing industry?
The hematologic malignancies testing market covered in this report is segmented –
1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type
2) By Product: Kits, Services
3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology
4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication
5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users
Subsegments:
1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)
2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis
3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis
4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis
5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests
View The Full Market Report:
What are the top market trends driving innovation in the hematologic malignancies testing industry?
Major companies operating in the hematologic malignancies testing market are focusing on developing innovative diagnostic approaches, such as rapid molecular profiling, to provide healthcare providers with precise and timely diagnostic tools that enhance early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic approach that analyzes a patient’s genetic makeup to identify mutations and variations, enabling faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, launched PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers such as leukemia, lymphoma, and multiple myeloma more accurately and quickly. The test identifies mutations in hundreds of genes in under 72 hours, significantly improving the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.
How are key players in the hematologic malignancies testing market strengthening their market position?
Major companies operating in the hematologic malignancies testing market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Aktiengesellschaft, Merck & Co. Inc., Bayer Aktiengesellschaft, AstraZeneca PLC, Abbott Laboratories, Novartis Aktiengesellschaft, GlaxoSmithKline Public Limited Company, Eli Lilly and Company, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Sun Pharmaceutical Industries Limited, Illumina Inc., Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Invitae Corporation, Adaptive Biotechnologies Corporation, Invivoscribe Inc.
Which geographic areas are contributing significantly to the growth of the hematologic malignancies testing sector?
North America was the largest region in the hematologic malignancies testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Hematologic Malignancies Testing Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24234&type=smp
Need Customized Data On Hematologic Malignancies Testing Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24234&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
